QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.061002v1 308/3/838    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Massi, P. Articles by Parolaro, D. Search for Related Content PubMed PubMed Citation Articles by Massi, P. Articles by Parolaro, D.

CELLULAR AND MOLECULAR

Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines

Department of Pharmacology, Chemotherapy and Toxicology (P.M., A.C.), and Department of Pharmacological Sciences, School of Pharmacy, and Center of Excellence for Neurodegenerative Diseases, University of Milan, Milan, Italy (S.C., M.P.A.); and Department of Structural and Functional Biology, Pharmacology Unit and Center of Neuroscience, University of Insubria, Busto Arsizio (Varese), Italy (A.V., D.P.)

Recently, cannabinoids (CBs) have been shown to possess antitumor properties. Because the psychoactivity of cannabinoid compounds limits their medicinal usage, we undertook the present study to evaluate the in vitro antiproliferative ability of cannabidiol (CBD), a nonpsychoactive cannabinoid compound, on U87 and U373 human glioma cell lines. The addition of CBD to the culture medium led to a dramatic drop of mitochondrial oxidative metabolism [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H tetrazolium bromide test] and viability in glioma cells, in a concentration-dependent manner that was already evident 24 h after CBD exposure, with an apparent IC₅₀ of 25 µM. The antiproliferative effect of CBD was partially prevented by the CB2 receptor antagonist N-[(1S)-endo-1,3,3-trimethylbicyclo[2,2,1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (SR144528; SR2) and -tocopherol. By contrast, the CB1 cannabinoid receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide hydrochloride (SR141716; SR1), capsazepine (vanilloid receptor antagonist), the inhibitors of ceramide generation, or pertussis toxin did not counteract CBD effects. We also show, for the first time, that the antiproliferative effect of CBD was correlated to induction of apoptosis, as determined by cytofluorimetric analysis and single-strand DNA staining, which was not reverted by cannabinoid antagonists. Finally, CBD, administered s.c. to nude mice at the dose of 0.5 mg/mouse, significantly inhibited the growth of subcutaneously implanted U87 human glioma cells. In conclusion, the nonpsychoactive CBD was able to produce a significant antitumor activity both in vitro and in vivo, thus suggesting a possible application of CBD as an antineoplastic agent.

Address correspondence to: Daniela Parolaro, Dept. of Structural and Functional Biology, Pharmacology Unit and Center of Neuroscience, University of Insubria, Via A. da Giussano 10, 21052 Busto Arsizio (Varese), Italy. E-mail: daniela.parolaro{at}uninsubria.it

This article has been cited by other articles:

				N. Pasquariello, G. Catanzaro, V. Marzano, D. Amadio, D. Barcaroli, S. Oddi, G. Federici, A. Urbani, A. Finazzi Agro, and M. Maccarrone Characterization of the Endocannabinoid System in Human Neuronal Cells and Proteomic Analysis of Anandamide-induced Apoptosis J. Biol. Chem., October 23, 2009; 284(43): 29413 - 29426. [Abstract] [Full Text] [PDF]

				S. D. McAllister, R. T. Christian, M. P. Horowitz, A. Garcia, and P.-Y. Desprez Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells Mol. Cancer Ther., November 1, 2007; 6(11): 2921 - 2927. [Abstract] [Full Text] [PDF]

				P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]

				A. Ligresti, A. S. Moriello, K. Starowicz, I. Matias, S. Pisanti, L. De Petrocellis, C. Laezza, G. Portella, M. Bifulco, and V. Di Marzo Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1375 - 1387. [Abstract] [Full Text] [PDF]

				R. J. McKallip, W. Jia, J. Schlomer, J. W. Warren, P. S. Nagarkatti, and M. Nagarkatti Cannabidiol-Induced Apoptosis in Human Leukemia Cells: A Novel Role of Cannabidiol in the Regulation of p22phox and Nox4 Expression Mol. Pharmacol., September 1, 2006; 70(3): 897 - 908. [Abstract] [Full Text] [PDF]

				G. Foltz, G.-Y. Ryu, J.-G. Yoon, T. Nelson, J. Fahey, A. Frakes, H. Lee, L. Field, K. Zander, Z. Sibenaller, et al. Genome-Wide Analysis of Epigenetic Silencing Identifies BEX1 and BEX2 as Candidate Tumor Suppressor Genes in Malignant Glioma. Cancer Res., July 1, 2006; 66(13): 6665 - 6674. [Abstract] [Full Text] [PDF]

				E. J. Carrier, J. A. Auchampach, and C. J. Hillard Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression PNAS, May 16, 2006; 103(20): 7895 - 7900. [Abstract] [Full Text] [PDF]

				H.-J. Zhu, J.-S. Wang, J. S. Markowitz, J. L. Donovan, B. B. Gibson, H. A. Gefroh, and C. L. DeVane Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 850 - 857. [Abstract] [Full Text] [PDF]

				F. A. de Jong, F. K. Engels, R. H.J. Mathijssen, L. van Zuylen, J. Verweij, R. P.H. Peters, and A. Sparreboom Medicinal Cannabis in Oncology Practice: Still a Bridge Too Far? J. Clin. Oncol., May 1, 2005; 23(13): 2886 - 2891. [Full Text] [PDF]

				I. Tegeder and G. Geisslinger Opioids As Modulators of Cell Death and Survival--Unraveling Mechanisms and Revealing New Indications Pharmacol. Rev., September 1, 2004; 56(3): 351 - 369. [Abstract] [Full Text] [PDF]